Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Preventive and therapeutic interventions for the microbiota

Florent Malard • 24 Aug 2020
EBMT 2020
General

Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, discusses preventative and therapeutic interventions in graft-versus-host disease (GvHD) post-allogenic stem cell transplantation, focusing on the microbiota. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Florent Malard

Outcomes of a real-world comparison of standard-of-care ide-cel and cilta-cel in R/R myeloma
0:55
Outcomes of a real-world comparison of standard-of-care ide-cel and cilta-cel in R/R myeloma
Florent Malard • 24 Mar 2026
MaaT013 pooled allogeneic microbiotherapy in refractory GI acute GvHD: results of the ARES trial
1:50
MaaT013 pooled allogeneic microbiotherapy in refractory GI acute GvHD: results of the ARES trial
Florent Malard • 24 Mar 2026
Results of a survey investigating fertility and outcomes after CAR T-cell therapy
1:13
Results of a survey investigating fertility and outcomes after CAR T-cell therapy
Florent Malard • 7 Dec 2025
Results of ARES: allogeneic microbiotherapy for ruxolitinib-refractory GvHD with GI involvement
2:08
Results of ARES: allogeneic microbiotherapy for ruxolitinib-refractory GvHD with GI involvement
Florent Malard • 7 Dec 2025

Related Videos

From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
2:58
From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
Iskra Pusic • 11 Sep 2026
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
3:46
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
Maher Salamoon • 8 Sep 2026
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
2:01
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
Michael Jain • 11 Sep 2026
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
1:46
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
Michael Jain • 11 Sep 2026
The content of VJHemOnc is intended for healthcare professionals